Expression of chemokine receptors in the different clinical forms of multiple sclerosis

Abstract

Chemokines and their receptors are important in the trafficking of peripheral leukocytes into the central nervous system, a major event in the pathogenesis of multiple sclerosis (MS). Evidence based on clinical, pathological and magnetic resonance imaging grounds supports some divergence between forms of MS with relapses [relapsing-remitting (RR) and secondary progressive (SP)] and the primary progressive (PP) form. To elucidate whether different pathogenic mechanisms are involved in PPMS, we compared membrane expression of a group of CC and CXC chemokine receptors (CCR1, CCR5, CXCR3, CXCR4) in peripheral blood of 68 MS patients (25 PPMS, 23 SPMS and 20 RRMS) and 26 healthy controls. We found a significant increase in surface expression of CCR5 in CD4⁺, CD8⁺, CD19⁺ and CD14⁺ cells as well as an increased percentage of CXCR3 and CXCR4 in CD14⁺ cells in MS patients compared to controls. Increased levels of CXCL10 (IP-10) and CCL5 (RANTES) in cerebrospinal fluid were also observed in a subgroup of MS patients. These results support that chemokines and their receptors are involved in the pathogenesis of MS. However, a pattern of chemokine-chemokine receptor expression characteristic of each clinical form of the disease failed to be observed.

Keywords

cerebrospinal fluid chemokine chemokine receptor multiple sclerosis primary progressive relapsing-remitting secondary progressive

References

Hartung HP , et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging . Ann Neurol 1995; 38: 186-193 .

Butcher E , Picker LJ. Lymphocyte homing and homeostasis . Science 1996; 272: 60-66 .

Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principle, problems and perspectives . Brain 1997; 120: 865-916 .

Ransohoff RM. Mechanisms of inflammation in MS tissue: adhesion molecules and chemokines . J Neuroimmunol 1999; 98: 57-68 .

Wu DT , et al. Mechanisms of leukocyte trafficking into the CNS . J Neurovirol 2000; 6(Suppl 1): S82-S85 .

Baggiolini M. Chemokines and leukocyte traffic . Nature 1998; 392: 565-568 .

McManus C , et al. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study . J Neuroimmunol 1998; 86: 20-29 .

Simpson JE , Newcombe J , Cuzner ML , Woodroofe MN. Expression of monocyte chemoattractant protein-1 and other b-chemokines by resident glia and inflammatory cell in multiple sclerosis lesions . J Neuroimmunol 1998; 84: 238-244 .

Simpson JE , Newcombe J , Cuzner ML , Woodroofe MN. Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions . Neuropathol Appl Neurobiol 2000; 26: 133-142 .

10.

Sorensen TL , et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients . J Clin Invest 1999; 103: 807-815 .

11.

Miyagishi R , Kikuchi S , Fukazawa T , Tashiro K. Macrophage inflammatory protein-1 alpha in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases . J Neurol Sci 1995; 129: 223-227 .

12.

Strunk T , et al. Increased numbers of CCR5+interferon-gamma and tumor-necrosis factor-alpha secreting T lymphocytes in multiple sclerosis patients . Ann Neurol 2000; 47: 269-273 .

13.

Thompson AJ , et al. Patterns of disease activity in multiple sclerosis: a clinical and magnetic resonance imaging study . BMJ 1990; 300: 631-634 .

14.

Thompson AJ , et al. Primary progressive multiple sclerosis . Brain 1997; 120: 1085-1096 .

15.

Revesz T , et al. A comparison of the pathology of primary and secondary progressive multiple sclerosis . Brain 1994; 117: 759-765 .

16.

Durán I , et al. Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules . Brain 1999; 122: 2297-2307 .

17.

Stevenson VL , et al. Primary progressive and transitional progressive multiple sclerosis: a clinical and MRI cross sectional study . Neurology 2000; 52: 839-845 .

18.

Balashov KE , Rottman JB , Weiner HL , Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions . Proc Natl Acad Sci USA 1999; 96: 6873-6878 .

19.

Poser CM , Paty DW , Scheinberg L. New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 1993; 13: 227-231 .

20.

Thompson AJ , et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper . Ann Neurol 2000; 47: 831-835 .

21.

Sallusto F , Lenig D , Mackay CR , Lanzavecchia A. Flexible programs of chemokine receptor expression of human polarized T helper 1 and 2 lymphocytes . J Exp Med 1998; 187: 875-883 .

22.

Zang YC , et al. Aberrant T cell migration toward RANTES and MIP-1 alpha in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5 . Brain 2000; 123: 1874-1882 .

23.

Strunk T , Bubel S , Mascher B , Schlenke P , Kirchner H , Wandinger KP. Increased numbers of CCR5+ interferon-gamma-and tumor necrosis factor-alpha-secreting T lymphocytes in multiple sclerosis patients . Ann Neurol 2000; 47: 269-273 .

24.

Sorensen TL , Sellebjerg F. Distinct chemokine receptor and cytokine expression profile in secondary progressive MS . Neurology 2001; 57: 1371-1376 .